drugset / Trial / NCT06241235
Study of ZG005 in Combination With Paclitaxel＋Platinum-based ± Bevacizumab in Patients With Advanced Cervical Carcinoma
RandomizedSequentialOpen-labelTreatment
Summary
This is a multicenter, open-label phase I/II study for the first-line treatment of advanced cervical cancer.
Timeline
- Start
- 2024-03-27
- Primary completion
- 2026-05
- Completion
- 2026-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | — | Intravenous |
| Subject | Carboplatin | Small molecule | — | Intravenous |
| Subject | Cisplatin | Other / unclassified | — | Intravenous |
| Subject | ZG005 | Unknown | 10 mg/kg | Intravenous |
| Subject | ZG005 | Unknown | 15 mg/kg | Intravenous |
| Background | Paclitaxel | Small molecule | — | Intravenous |